Search results for " inflammatory bowel diseas"

showing 10 items of 66 documents

Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve p…

2018

Background: In the absence of head-to-head trials, there is an unmeet need to better understand the relative effectiveness of different biologics in inflammatory bowel disease (IBD). The Sicilian Network for Inflammatory Bowel Disease (SN-IBD) is a group composed by all Sicilian centres which continuously enter in a web-based software all clinical data of IBD patients treated with biologics. Methods: Data of all incident Crohn’s disease (CD) patients treated with infliximab (IFX) and adalimumab (ADA) from January 2013 to April 2017 were extracted from the cohort of SN-IBD. Patients were divided in biologic-naïve and non-naïve, and the two groups were analysed singularly. We used a one-to-tw…

Sicilian Network; Inflammatory Bowel Disease; SN-IBDSicilian NetworkSettore MED/09 - Medicina InternaInflammatory Bowel DiseaseSN-IBD
researchProduct

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

2020

Telemedicinemedicine.medical_specialtytelemedicine; COVID-19; inflammatory bowel disease; Aftercare; Betacoronavirus; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicinePneumonia ViralAftercareInflammatory bowel diseaselaw.inventionSettore MED/12Betacoronaviruslawinflammatory bowel diseaseSurveys and QuestionnairesmedicineInfection controlImmunology and AllergyHumansMass ScreeningViralLetters to the EditorPandemicsMass screeningAcademicSubjects/MED00260Remote ConsultationCOVID-19; inflammatory bowel disease; telemedicine; Aftercare; Betacoronavirus; COVID-19; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; SARS-CoV-2; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicineInfection Controlbusiness.industrySARS-CoV-2Remote ConsultationGastroenterologyCOVID-19PneumoniaBiological productmedicine.diseaseInflammatory Bowel DiseasesIntensive care unitOrganizational InnovationTelemedicineHospitalizationDiarrheaItalyEmergency medicinemedicine.symptomtelemedicine; COVID-19; inflammatory bowel diseasebusinessCoronavirus InfectionsHospital UnitsInflammatory Bowel Diseases
researchProduct

Highlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy

2023

Inflammatory Bowel diseases (IBDs) constitute a complex panel of disorders characterized with chronic inflammation affecting the alimentary canal along with extra intestinal manifestations. Its exact etiology is still unknown; however, it seems to be the result of uncharacterized environmental insults in the intestine and their immunological consequences along with dysbiosis, in genetically predisposed individuals. It was the main target of our team since 2002 to explore the etiology of IBD and the related role of bacteria. For almost two decades, our laboratory, among others, has been involved in the reciprocal interaction between the host gastrointestinal lining and the homing microbiota.…

TransplantationColorectal cancer Inflammatory bowel diseaseMicrobiotaProbiotics.Settore BIO/16 - Anatomia UmanaImmunologyImmunology and AllergyTransplant Immunology
researchProduct

Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68)

2016

Background & Aims: A novel family of proton-sensing G-proteinâcoupled receptors, including ovarian cancer G-proteinâcoupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1α. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. Methods: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and…

WT wild type0301 basic medicineMM6 MonoMac 6HV healthy volunteerSPARC secreted protein acidic and rich in cysteineNF-κB nuclear factor-κBInflammationBiologyIEC intestinal epithelial cell03 medical and health sciencesIntestinal mucosaTDAG8Ovarian Cancer G-Protein–Coupled ReceptormedicineOGR1 ovarian cancer G-protein–coupled receptor 1 (GPR68)IFN interferonlcsh:RC799-869ReceptorOriginal ResearchTh T-helperInflammationTNF tumor necrosis factorIBD inflammatory bowel diseaseHepatologyRT-qPCR quantitative reverse-transcription polymerase chain reactionAICAR 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranosideTDAG8 T-cell death-associated gene 8 (GPR65)Inflammatory Bowel DiseaseGRP65GastroenterologyHypoxia (medical)Molecular biologyGPR G-protein–coupled receptormRNA messenger RNAIL interleukinChIP chromatin immunoprecipitationHIF hypoxia-inducible factorUC ulcerative colitis030104 developmental biologyHypoxia-inducible factorsCancer researchCD Crohn's diseaselcsh:Diseases of the digestive system. GastroenterologyTumor necrosis factor alphaFCS fetal calf serummedicine.symptomChromatin immunoprecipitationHomeostasisCellular and Molecular Gastroenterology and Hepatology
researchProduct

Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase

2015

Background & Aims: Plasma levels of high-density lipoprotein (HDL) cholesterol are frequently found decreased in patients with inflammatory bowel disease (IBD). Therefore, and because HDL exerts anti-inflammatory activities, we investigated whether HDL and its major protein component apolipoprotein A-I (apoA-I) modulate mucosal inflammatory responses in vitro and in vivo. Methods: The human intestinal epithelial cell line T84 was used as the in vitro model for measuring the effects of HDL on the expression and secretion of tumor necrosis factor (TNF), interleukin-8 (IL-8), and intracellular adhesion molecule (ICAM). Nuclear factor-κB (NF-κB)-responsive promoter activity was studied by …

WT wild typeApolipoprotein BEMSA electrophoretic mobility shift assayMPO myeloperoxidaseIκB kinaseDSS dextran sodium sulphatemTOR the mammalian target of rapamycinRT-PCR real-time polymerase chain reactionNF-κBchemistry.chemical_compound540 ChemistryApoA-I apolipoprotein A-I10038 Institute of Clinical ChemistryOriginal ResearchTNF tumor necrosis factorbiologyIBD inflammatory bowel diseaseChemistryGastroenterologyMyeloperoxidase10076 Center for Integrative Human PhysiologyMEICS murine endoscopic index of colitis severityTumor necrosis factor alphalipids (amino acids peptides and proteins)3-MA 3-methyl adenineNF-κB nuclear factor κBHDL high-density lipoproteinLC3II light chain 3 IIPBS phosphate-buffered salinep-IKK phosphorylated IκB kinase610 Medicine & healthICAM intracellular adhesion molecule246-Trinitrobenzenesulfonic acidTg transgenicmedicineAutophagyCD Crohn’s disease2715 GastroenterologyColitislcsh:RC799-869KO knockoutHepatologyApolipoprotein A-IAutophagyInflammatory Bowel DiseaseTNBS 246-trinitrobenzenesulfonic acidmedicine.diseaseMolecular biologyIL interleukinsiRNA small interfering RNAPI-3 phosphatidylinositol-3Immunologybiology.protein2721 Hepatologylcsh:Diseases of the digestive system. GastroenterologyPFA paraformaldehydeLipoproteinDAPI 4′6-diamidino-2-phenylindoleCMGH Cellular and Molecular Gastroenterology and Hepatology
researchProduct

A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sic…

2017

Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance treatment of moderate-to-severe ulcerative colitis (UC). No comparable data between the 2 drugs are available up to now. Aims & Methods: We reported the Sicilian Network experience on the comparative efficacy of ADA and GOL in patients (pts) with moderate-to-severe UC. From June 2015 until April 2017, 197 consecutive pts with moderate to severe UC were treated with ADA or GOL. The efficacy was evaluated at 8 week and at the end of the follow up considering ‘‘clinical response’’ (reduction of at least 2 points of Partial Mayo Score with concomitant steroid reduction or discontinuation) and “…

adalimumab; golimumab; ulcerative colitis; sicilian network; inflammatory bowel disease; SN-IBDsicilian networkSettore MED/09 - Medicina Internainflammatory bowel diseaseadalimumabSN-IBDgolimumabulcerative coliti
researchProduct

Comment to “Management of cytomegalovirus infection in inflammatory bowel diseases”

2012

.

cytomegaloviruHepatologybusiness.industryGastroenterologyInflammatory Bowel DiseasesAntiviral AgentsInflammatory bowel diseaseCytomegalovirus infectionCrohn DiseaseCytomegalovirus InfectionsImmunologyHumansMedicineColitis Ulcerativecytomegalovirus; Inflammatory bowel diseasebusinessGanciclovircytomegalovirusImmunosuppressive AgentsDigestive and Liver Disease
researchProduct

IBD, malignancy and oral microbiota: Analysis of the literature

2016

The human microbiota, in adults, varies in number and species based on the location in the gastrointestinal tract. The highest concentration is at the intestinal level, where mainly Bacteroidetes, Actinobacteria, Firmicutes and proteobacteria are found. Instead, in the oral cavity, five major phyla exists. Firmicutes, Actinobacteria, Proteobacteria, Bacteroidetes and Fusobacteria. Variations in the microbiota cause bysbiosis, which is responsible to a great extent for the onset of many diseases including inflammatory bowel disease (IBD) and colorectal cancer (CRC). In some cases (8-10%) IBD has shown oral manifestations that may reflect a change in the composition of the oral microbiota. Th…

dysbiosis gut microbiota Inflammatory Bowel Diseases colorectal cancer CRC IBDSettore MED/12 - GastroenterologiaSettore MED/06 - Oncologia Medica
researchProduct

The influence of some dietary components on intestinal microbiota

2016

The gut microbiota is the set of symbiotic microorganisms that resides in our intestine. The interaction between the gut microbiota and the mucosal immune system can be altered as a result of shifts in the composition or metabolic activity of the intestinal microflora. Recent studies establish that diet is one of the main involved factors in determining the microbial composition of the gut suggesting its role as external factor able to promote the onset of specific diseases by disrupting the immune homeostasis. Starting from the evidence that the 57% of the gut microbiota’s entire variation are due to dietary alterations this review aims at providing an overview of the positive impact of so…

dysbiosis gut microbiota diet inflammatory bowel disease IBDSettore MED/18 - Chirurgia GeneraleSettore MED/12 - GastroenterologiaSettore MED/07 - Microbiologia E Microbiologia Clinica
researchProduct

The intestinal ecosystem and probiotics

2016

The term "probiotic" comes from the greek "pro bios" and means "pro life": Nowadays, an increasing number of pharmaceutical preparations and functional foods are enriched with probiotics and for the patients it is increasingly important to receive information needed to know how to orient in the choice. The benefits from probiotics are many and include the modulation of the intestinal microflora (stimulation of beneficial bacteria and inhibition of pathogens), the support of bowel function and the stimulation of the immune system. This broad spectrum of beneficial effects to maintain efficient the intestinal ecosystem. Therefore, probiotics are an useful tool to prevent the formation of diso…

dysbiosis intestinal microflora Inflammatory Bowel Disease IBD probiotics
researchProduct